Streetbeat News

Price Targets

CRWD

CrowdStrike Holdings' stock (CRWD) is trading higher following an analyst update from JMP Securities, which maintained a Market Outperform rating and increased the price target from $235 to $330.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 7:55 pm

OLN

Barclays analyst Michael Leithead has maintained an Equal-Weight rating on Olin Corporation (NYSE:OLN) and increased the price target from $49 to $57. This adjustment reflects a positive view on the stock's potential performance.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 7:54 pm

BE

BFRG

CDLX

PBLA

SNCE

SOFI

U.S. stocks saw a slight increase, with the Nasdaq Composite up by 75 points. The Dow and S&P 500 also experienced modest gains. Consumer discretionary shares led the gains, while energy shares declined following a 1.3% drop in crude oil prices. Science 37 Holdings (SNCE) surged 16% after agreeing to be acquired by eMed. SoFi Technologies (SOFI) jumped 16% on strong quarterly revenue, and Cardlytics (CDLX) rose 28% after a settlement agreement and updated Q4 results. Conversely, Panbela Therapeutics (PBLA) plummeted 67% due to a public offering, Bullfrog AI Holdings (BFRG) fell 24% after a shelf offering, and Bloom Energy (BE) dropped 7% after a downgrade by B of A Securities. The Federal Reserve Bank of Dallas reported a decline in Texas manufacturing activity.

Portfolio Pulse from Avi Kapoor

January 29, 2024 | 7:24 pm

CL

Raymond James analyst Olivia Tong upgraded Colgate-Palmolive Co (NYSE:CL) to Outperform from Market Perform with a $91 price target, citing strong Q4 FY23 earnings and positive 2024 outlook. The company reported a 7% YOY sales growth, beating estimates, and expects 1%-4% net sales growth for FY24. Risks in Latin America are noted, but offset by strengths in Mexico and Brazil. Wells Fargo, UBS, and Morgan Stanley analysts also raised their price targets for CL, reflecting a positive sentiment among analysts.

Portfolio Pulse from Lekha Gupta

January 29, 2024 | 7:08 pm

FCNCA

Wedbush analyst David Chiaverini has reiterated an Outperform rating on First Citizens BancShares (NASDAQ:FCNCA) and maintained a price target of $1800.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 7:06 pm

NVDA

Cantor Fitzgerald analyst C J Muse has reiterated an Overweight rating on NVIDIA Corporation (NASDAQ:NVDA) and maintained a price target of $775.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 7:02 pm

RXST

Over the past three months, 8 analysts have provided ratings for RxSight (NASDAQ:RXST), with sentiments ranging from bullish to bearish. The average 12-month price target for RXST is $42.38, with a high of $54.00 and a low of $30.00, marking a 3.37% increase from the previous target of $41.00. Analysts from firms like Oppenheimer, Needham, Wells Fargo, Stifel, and Morgan Stanley have updated their ratings and price targets, reflecting their views on the company's market performance. RxSight, a medical technology company, has shown a revenue growth of 75.97% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -55.93%, ROE of -7.79%, and ROA of -6.58%. The company has a low debt-to-equity ratio of 0.02.

Portfolio Pulse from Benzinga Insights

January 29, 2024 | 7:00 pm

LRCX

Cantor Fitzgerald analyst C J Muse has reiterated a Neutral rating on Lam Research (NASDAQ:LRCX) and maintained a price target of $900.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 6:57 pm

KLAC

Cantor Fitzgerald analyst C J Muse has reiterated a Neutral rating on KLA Corporation (NASDAQ:KLAC) and maintained a price target of $625.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 6:55 pm

AVGO

Cantor Fitzgerald analyst C J Muse has reiterated an Overweight rating on Broadcom (NASDAQ:AVGO) and maintained a price target of $1300.

Portfolio Pulse from Benzinga Newsdesk

January 29, 2024 | 6:52 pm